⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7838226 | 1.00 | — | — | |
| SCHEMBL12423934 | 1.00 | — | — | |
| SCHEMBL65034 | 1.00 | — | — | |
| SCHEMBL7838230 | 1.00 | — | — | |
| SCHEMBL6264527 | 0.93 | CHRNB4 (0.41) | — | |
| SCHEMBL8339817 | 0.83 | — | — | |
| SCHEMBL20879730 | 0.83 | — | — | |
| SCHEMBL6891743 | 0.80 | — | — | |
| SCHEMBL2756894 | 0.80 | — | — | |
| SCHEMBL1615410 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-12600717-B2 | Tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4719603-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720678-A1 | SURVIVIN AS A BIOMARKER FOR PREDICTING THE RESPONSIVENESS OF CANCER TREATMENT | Boehringer Ingelheim International GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| US-20260069605-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4688784-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12545670-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-02-10 | — | — | US | disclosed |
| US-20260022132-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | TREELINE BIOSCIENCES INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260015344-A1 | PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| CN-115702025-A | Fused tricyclic KRAS inhibitors | 因赛特公司 | 2023-02-14 | — | — | CN | disclosed |
| WO-2023287896-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023283213-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022266015-A1 | FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS | KUMQUAT BIOSCIENCES INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266015-A1 | FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS | KUMQUAT BIOSCIENCES INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220306633-A1 | IMIDAZOLE AND TRIAZOLE KRAS INHIBITORS | INCYTE CORPORATION | 2022-09-29 | — | — | US | disclosed |
| WO-2022204112-A1 | IMIDAZOLE AND TRIAZOLE KRAS INHIBITORS | INCYTE CORPORATION (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20210380574-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2021-12-09 | — | — | US | disclosed |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION | 2021-11-18 | — | — | US | disclosed |
| WO-2021211864-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION (US) | 2021-10-21 | — | — | WO | disclosed |